142 related articles for article (PubMed ID: 18324799)
1. Cross-docking of inhibitors into CDK2 structures. 1.
Duca JS; Madison VS; Voigt JH
J Chem Inf Model; 2008 Mar; 48(3):659-68. PubMed ID: 18324799
[TBL] [Abstract][Full Text] [Related]
2. Cross-docking of inhibitors into CDK2 structures. 2.
Voigt JH; Elkin C; Madison VS; Duca JS
J Chem Inf Model; 2008 Mar; 48(3):669-78. PubMed ID: 18324800
[TBL] [Abstract][Full Text] [Related]
3. Protein-ligand docking accounting for receptor side chain and global flexibility in normal modes: evaluation on kinase inhibitor cross docking.
May A; Zacharias M
J Med Chem; 2008 Jun; 51(12):3499-506. PubMed ID: 18517186
[TBL] [Abstract][Full Text] [Related]
4. Protein structures in virtual screening: a case study with CDK2.
Thomas MP; McInnes C; Fischer PM
J Med Chem; 2006 Jan; 49(1):92-104. PubMed ID: 16392795
[TBL] [Abstract][Full Text] [Related]
5. Virtual screening to enrich a compound collection with CDK2 inhibitors using docking, scoring, and composite scoring models.
Cotesta S; Giordanetto F; Trosset JY; Crivori P; Kroemer RT; Stouten PF; Vulpetti A
Proteins; 2005 Sep; 60(4):629-43. PubMed ID: 16028223
[TBL] [Abstract][Full Text] [Related]
6. Prediction of multiple binding modes of the CDK2 inhibitors, anilinopyrazoles, using the automated docking programs GOLD, FlexX, and LigandFit: an evaluation of performance.
Sato H; Shewchuk LM; Tang J
J Chem Inf Model; 2006; 46(6):2552-62. PubMed ID: 17125195
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking of balanol to dynamics snapshots of protein kinase A.
Wong CF; Kua J; Zhang Y; Straatsma TP; McCammon JA
Proteins; 2005 Dec; 61(4):850-8. PubMed ID: 16245317
[TBL] [Abstract][Full Text] [Related]
8. RosettaLigand docking with full ligand and receptor flexibility.
Davis IW; Baker D
J Mol Biol; 2009 Jan; 385(2):381-92. PubMed ID: 19041878
[TBL] [Abstract][Full Text] [Related]
9. QM/MM as a tool in fragment based drug discovery. A cross-docking, rescoring study of kinase inhibitors.
Gleeson MP; Gleeson D
J Chem Inf Model; 2009 Jun; 49(6):1437-48. PubMed ID: 19459698
[TBL] [Abstract][Full Text] [Related]
10. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
11. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
[TBL] [Abstract][Full Text] [Related]
12. Addressing limitations with the MM-GB/SA scoring procedure using the WaterMap method and free energy perturbation calculations.
Guimarães CR; Mathiowetz AM
J Chem Inf Model; 2010 Apr; 50(4):547-59. PubMed ID: 20235592
[TBL] [Abstract][Full Text] [Related]
13. An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation--a case study with CDK2/cyclinA.
Mascarenhas NM; Ghoshal N
Eur J Med Chem; 2008 Dec; 43(12):2807-18. PubMed ID: 18037537
[TBL] [Abstract][Full Text] [Related]
14. Supervised consensus scoring for docking and virtual screening.
Teramoto R; Fukunishi H
J Chem Inf Model; 2007; 47(2):526-34. PubMed ID: 17295466
[TBL] [Abstract][Full Text] [Related]
15. Role of binding entropy in the refinement of protein-ligand docking predictions: analysis based on the use of 11 scoring functions.
Ruvinsky AM
J Comput Chem; 2007 Jun; 28(8):1364-72. PubMed ID: 17342720
[TBL] [Abstract][Full Text] [Related]
16. Optimizing fragment and scaffold docking by use of molecular interaction fingerprints.
Marcou G; Rognan D
J Chem Inf Model; 2007; 47(1):195-207. PubMed ID: 17238265
[TBL] [Abstract][Full Text] [Related]
17. Insights into the structural basis of N2 and O6 substituted guanine derivatives as cyclin-dependent kinase 2 (CDK2) inhibitors: prediction of the binding modes and potency of the inhibitors by docking and ONIOM calculations.
Alzate-Morales JH; Caballero J; Vergara Jague A; González Nilo FD
J Chem Inf Model; 2009 Apr; 49(4):886-99. PubMed ID: 19323453
[TBL] [Abstract][Full Text] [Related]
18. Towards more accurate pharmacophore modeling: Multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2.
Zou J; Xie HZ; Yang SY; Chen JJ; Ren JX; Wei YQ
J Mol Graph Model; 2008 Nov; 27(4):430-8. PubMed ID: 18786843
[TBL] [Abstract][Full Text] [Related]
19. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
Griffin RJ; Henderson A; Curtin NJ; Echalier A; Endicott JA; Hardcastle IR; Newell DR; Noble ME; Wang LZ; Golding BT
J Am Chem Soc; 2006 May; 128(18):6012-3. PubMed ID: 16669651
[TBL] [Abstract][Full Text] [Related]
20. Nonlinear scoring functions for similarity-based ligand docking and binding affinity prediction.
Brylinski M
J Chem Inf Model; 2013 Nov; 53(11):3097-112. PubMed ID: 24171431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
